AstraZeneca raises sales forecast after surge in cancer drugs
Share:
(Reuters) - AstraZeneca lifted its annual drug sales forecast for the second time this year after a surge in revenue from newer cancer treatments, but warned that changing policies in China, its second-biggest market, would crimp growth next year.The British drugmaker, which halted years of falling sales in 2018, on Thursday reported growth of up to 80% for a raft of newer medicines in its portfolio, including treatments for diabetes, heart conditions and cancer.Its shares were nearly 4% higher..